5月27日，波士顿科学盘前下跌3.11%，报55.83美元/股，成交额149.86万美元。
消息面上，高盛将波士顿科学目标价从84美元下调至81美元，维持买入评级。据FactSet统计，该股当前分析师平均目标价为83.63美元。此外，FDA近期披露波士顿科学将对部分起搏器进行软件升级召回，或对市场情绪形成一定压制。
基本面方面，公司一季度每股收益0.90美元，归母净利润13.41亿美元，同比增长98.96%，营收52.03亿美元，同比增长11.58%。战略层面，公司近期向TAVR开发商MiRus投资15亿美元，重返经导管主动脉瓣置换赛道，挑战美敦力与爱德华生命科学双寡头格局。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.